83
Growth Score in past quarter
pts
Heat Score 83 in past quarter
23 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
72404
CellCarta highly trained, multi-disciplinary team has developed a highly integrated, industrialized approach to proteomics.
- Carol E. Berry: Chief Commercial Officer & SVPPast Role: Asuragen, Sr. Vice President, GM Pharmacogenomic Services Division
- Ehab El-Gabry: Chief Medical Officer and Head of Companion DiagnosticsPast Role: Daiichi Sankyo, Senior Medical Director, US Medical Affairs Oncology Diagnostics
About the Company
CellCarta's Mission is centered on collaborating and partnering with pharmaceutical and biotech companies through proteomics and immune monitoring enabling the acceleration of precision medicine in drug development. With a vision and deep understanding of the needs for complex immune monitoring in novel drug development, Caprion integrated
ImmuneCarta (formerly known as National Immune Monitoring), with its established and proven proteomics service, ProteoCarta. Together, Caprion now offers a fully integrated and unique service offering to its partners.

